Interlaboratory study of 4 versions of a therapeutic protein drug—all manufactured from living cells—reports that an established analytical tool akin to magnetic resonance imaging reliably assessed atomic structures of biologically similar products, yielding equivalent of a fingerprint for each. Described in Nature Biotechnology, findings demonstrate that 2D nuclear magnetic resonance spectroscopy can be a powerful complementary technique for companies and regulators when assessing biosimilars.